EUROPEAN COMMISSION

Brussels, 21.8.2024
C(2024) 5981 final

PUBLIC VERSION

Platinum Equity, LLC
360 North Crescent Drive
Beverly Hills, California 90210
United States of America

Subject: **Case M.11628 - PLATINUM EQUITY GROUP / SUNRISE MEDICAL**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 29 July 2024, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which Platinum Equity Group (USA) will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of Cidron Ollopa Investment B.V., Capnor SM AB, Capnor SM2 AB and Sunrise Medical (US) LLC (together 'Sunrise Medical', Germany) by way of purchase of shares. ([3])

(2) The business activities of the undertakings concerned are the following:

– Platinum Equity Group specializes in the merger, acquisition and operation of companies that provide services and solutions to customers in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing, and distribution,

– Sunrise Medical is active in distribution, manufacturing and research and development of mobility solutions for mobility impaired individuals, focusing on manual and power wheelchairs, motorised scooters, seating and positioning systems and daily living aids.

(3) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2024/4912, 5.8.2024.

paragraph 5(c) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(4) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').